Interactions of Abiraterone, Eplerenone, and Prednisolone With Wild-Type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining With MDV3100

Cancer Research - United States
doi 10.1158/0008-5472.can-11-3980
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Porphyrin Interactions With Wild-Type and Mutant Mouse Ferrochelatase†

Biochemistry
Biochemistry
2000English

Prognostic Factors for Patients Treated With Abiraterone

Future Science OA
MedicineBiotechnology
2019English

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Cost-Effectiveness Analysis of Abiraterone, Docetaxel or Placebo Plus Androgen Deprivation Therapy for Hormone-Sensitive Advanced Prostate Cancer

Einstein (São Paulo, Brazil)
Medicine
2019English

Pih13 - Abiraterone: A Single-Centre Experience

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients

European urology oncology
OncologyRadiologyUrologyNuclear MedicineImagingSurgery
2019English

Structures of Cytochrome P450 17A1 With Prostate Cancer Drugs Abiraterone and TOK-001

Nature
Multidisciplinary
2012English

Activity of Abiraterone in Rechallenging Two AR-expressing Salivary Gland Adenocarcinomas, Resistant to Androgen-Deprivation Therapy

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2014English

Pd28-04 Detection of Androgen Receptor Variant 7 (Ar-V7) in Whole Blood Rna of Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Treated With Abiraterone Acetate (Abi)

Journal of Urology
Urology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy